^
CANCER:
Hepatocellular Cancer
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
palbociclib + alpelisib Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
palbociclib + alpelisib Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
alpelisib + TAK-228 Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
alpelisib + TAK-228 Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
PIK3CA E545K
|
HCC
|
PIK3CA E545K
|
HCC
|
alpelisib Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
alpelisib Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
alpelisib Resistant: D – Preclinical
Cell Death Dis - 2 weeks
|
alpelisib Resistant: D – Preclinical
Cell Death Dis - 2 weeks
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
cabozantinib tablet Sensitive: A1 - Approval
|
cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
NTRK3 fusion
|
HCC
|
NTRK3 fusion
|
HCC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
HCC
|
NTRK2 fusion
|
HCC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
HCC
|
NTRK1 fusion
|
HCC
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
HCC
|
NTRK3 fusion
|
HCC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
HCC
|
NTRK2 fusion
|
HCC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
HCC
|
NTRK1 fusion
|
HCC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
sirolimus Sensitive: A2 - Guideline
|
sirolimus Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
HCC
|
MSI-H/dMMR
|
HCC
|
dostarlimab Sensitive: A2 - Guideline
NCCN - 4 weeks
|
dostarlimab Sensitive: A2 - Guideline
NCCN - 4 weeks
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
FGF21-H
|
HCC
|
FGF21-H
|
HCC
|
lenvatinib Sensitive: B - Late Trials
|
lenvatinib Sensitive: B - Late Trials
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
SRF388 Sensitive: B - Late Trials
|
SRF388 Sensitive: B - Late Trials
|
HGF-H + VEGFA-H
|
HCC
|
HGF-H + VEGFA-H
|
HCC
|
erlotinib + sorafenib Resistant: B - Late Trials
|
erlotinib + sorafenib Resistant: B - Late Trials
|
VEGFA-H
|
HCC
|
VEGFA-H
|
HCC
|
lenvatinib Resistant: B - Late Trials
|
lenvatinib Resistant: B - Late Trials
|
FGFR2 fusion
|
HCC
|
FGFR2 fusion
|
HCC
|
infigratinib Sensitive: C1 - Off-label
|
infigratinib Sensitive: C1 - Off-label
|
PD-L1 expression
|
HCC
|
PD-L1 expression
|
HCC
|
lenvatinib Sensitive: C2 – Inclusion Criteria
|
lenvatinib Sensitive: C2 – Inclusion Criteria
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria
|
sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria
|
TSC2 overexpression
|
HCC
|
TSC2 overexpression
|
HCC
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
FOXA3 overexpression
|
HCC
|
FOXA3 overexpression
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
CXCL12-H
|
HCC
|
CXCL12-H
|
HCC
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
KDR-H
|
HCC
|
KDR-H
|
HCC
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
VEGFA-H
|
HCC
|
VEGFA-H
|
HCC
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
ST6GAL1 elevation
|
HCC
|
ST6GAL1 elevation
|
HCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
ARID1A mutation
|
HCC
|
ARID1A mutation
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
HCC
|
PD-L1 expression
|
HCC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 expression
|
HCC
|
PD-L1 expression
|
HCC
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
GPC3 overexpression
|
HCC
|
GPC3 overexpression
|
HCC
|
atezolizumab + RG7686 Sensitive: C3 – Early Trials
|
atezolizumab + RG7686 Sensitive: C3 – Early Trials
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
ANGPT2-H
|
HCC
|
ANGPT2-H
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
FGF19-H
|
HCC
|
FGF19-H
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
FGF19-L
|
HCC
|
FGF19-L
|
HCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
ANGPT2-L
|
HCC
|
ANGPT2-L
|
HCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
FGFR4 G388R + NOS3 rs2070744
|
HCC
|
FGFR4 G388R + NOS3 rs2070744
|
HCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
miR-216a-3p overexpression
|
HCC
|
miR-216a-3p overexpression
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
HES1 overexpression
|
HCC
|
HES1 overexpression
|
HCC
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
Tregs-H
|
HCC
|
Tregs-H
|
HCC
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
KDR overexpression
|
HCC
|
KDR overexpression
|
HCC
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
PAK4 deletion
|
HCC
|
PAK4 deletion
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
HCC
|
CDKN2A deletion
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
Chr amplification(11)(q23)
|
HCC
|
Chr amplification(11)(q23)
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HOXC8 overexpression
|
HCC
|
HOXC8 overexpression
|
HCC
|
oxaliplatin Sensitive: C3 – Early Trials
|
oxaliplatin Sensitive: C3 – Early Trials
|
ATP5IF1 overexpression
|
HCC
|
ATP5IF1 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
PI16 overexpression
|
HCC
|
PI16 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
TGFB1 elevation
|
HCC
|
TGFB1 elevation
|
HCC
|
sorafenib + LY2157299 Sensitive: C3 – Early Trials
|
sorafenib + LY2157299 Sensitive: C3 – Early Trials
|
VEGFA elevation
|
HCC
|
VEGFA elevation
|
HCC
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
KRAS G13D
|
HCC
|
KRAS G13D
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS Q61H
|
HCC
|
KRAS Q61H
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS A146T
|
HCC
|
KRAS A146T
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12V
|
HCC
|
KRAS G12V
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12S
|
HCC
|
KRAS G12S
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12R
|
HCC
|
KRAS G12R
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12D
|
HCC
|
KRAS G12D
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12C
|
HCC
|
KRAS G12C
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12A
|
HCC
|
KRAS G12A
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61R
|
HCC
|
NRAS Q61R
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61L
|
HCC
|
NRAS Q61L
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61K
|
HCC
|
NRAS Q61K
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61H
|
HCC
|
NRAS Q61H
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
FGF19 positive
|
HCC
|
FGF19 positive
|
HCC
|
BLU-554 Sensitive: C3 – Early Trials
|
BLU-554 Sensitive: C3 – Early Trials
|
FGF19 negative
|
HCC
|
FGF19 negative
|
HCC
|
BLU-554 Resistant: C3 – Early Trials
|
BLU-554 Resistant: C3 – Early Trials
|
FGF19 overexpression
|
HCC
|
FGF19 overexpression
|
HCC
|
BLU-554 Sensitive: C3 – Early Trials
|
BLU-554 Sensitive: C3 – Early Trials
|
FGF4 amplification
|
HCC
|
FGF4 amplification
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
FGF3 amplification
|
HCC
|
FGF3 amplification
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
ADAM9 underexpression
|
HCC
|
ADAM9 underexpression
|
HCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
TGFB1-H
|
HCC
|
TGFB1-H
|
HCC
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
CD133 overexpression
|
HCC
|
CD133 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
THY1 overexpression
|
HCC
|
THY1 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
EFNB2 negative
|
HCC
|
EFNB2 negative
|
HCC
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
EFNB2 positive
|
HCC
|
EFNB2 positive
|
HCC
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
sEphB4-HSA Sensitive: C3 – Early Trials
|
PD-L1 expression
|
HCC
|
PD-L1 expression
|
HCC
|
SNG-162 Sensitive: C3 – Early Trials
|
SNG-162 Sensitive: C3 – Early Trials
|
S100A16 overexpression
|
HCC
|
S100A16 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
S100A8 overexpression
|
HCC
|
S100A8 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
KPNA3 underexpression
|
HCC
|
KPNA3 underexpression
|
HCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
PCSK9 underexpression
|
HCC
|
PCSK9 underexpression
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
NFE2L2 overexpression
|
HCC
|
NFE2L2 overexpression
|
HCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
MET overexpression
|
HCC
|
MET overexpression
|
HCC
|
tepotinib Sensitive: C3 – Early Trials
|
tepotinib Sensitive: C3 – Early Trials
|
ASS1 negative
|
HCC
|
ASS1 negative
|
HCC
|
BCT-100 Sensitive: C3 – Early Trials
|
BCT-100 Sensitive: C3 – Early Trials
|
KMT2C mutation
|
HCC
|
KMT2C mutation
|
HCC
|
PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
|
PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
|
DDR
|
HCC
|
DDR
|
HCC
|
FOLFOX Sensitive: C3 – Early Trials
|
FOLFOX Sensitive: C3 – Early Trials
|
GPC3 positive
|
HCC
|
GPC3 positive
|
HCC
|
CAR-T immunotherapy Sensitive: C3 – Early Trials
|
CAR-T immunotherapy Sensitive: C3 – Early Trials
|
FGF19 positive
|
HCC
|
FGF19 positive
|
HCC
|
H3B-6527 Sensitive: C3 – Early Trials
|
H3B-6527 Sensitive: C3 – Early Trials
|
ANGPT2-L
|
HCC
|
ANGPT2-L
|
HCC
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
